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ABSTRACT
Mutations in the TSC2 gene, coding for the tumour suppressor protein
Tuberin, lead to formation of benign tumours in systems like the brain. Some data
supports Tuberin being an essential regulator of neural development and playing
a role in cell fate decisions.
I hypothesized that Tuberin is an essential regulator of neural cell fate
decisions in the cerebellum and mutations in Tuberin may fuel the expansion of a
stem-like population of cells in the childhood malignant brain cancer
Medulloblastoma (MB). I found that Tuberin levels were tightly regulated in select
regions of the brain. Culture of

primary cerebellum stem/progenitor cells was

performed. I demonstrated that Tuberin levels are downregulated throughout cell
differentiation. Tuberin levels are high in the stem-like population in MB
cells. This supports that Tuberin is an essential regulator of differentiation in
stem-like progenitor population. Coaxing this stem-cell population to undergo
functional differentiation in MB is one potentially exciting area for new cancer
therapy.
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INTRODUCTION

I.

Tuberin: A Tumour Suppressor
It is crucial to maintain cellular homeostasis within a growing population of cells in the

body. The process of cellular growth involves a series of controlled and regulated divisions.
There are many different factors that keep the process of cellular growth and cellular death in
balance. Genes that achieve this purpose are called tumour suppressor genes. A tumour
suppressor gene is mainly defined as an anti-oncogene; thereby, preventing cells from becoming
cancerous1. Generally, a tumour suppressor gene hinders cell proliferation and slows down the
cell cycle. Mutations that lead to uncontrolled cell growth, which with further cooperating
mutations, can lead to cancer formation 1.
For tumour suppressor genes to lose their inhibitory function, the requirements for the
“two hit hypothesis” must be met. Established by Alfred Knudson, the “two hit hypothesis”
proposes that tumour suppressor genes must lose both functional copies to contribute to the
oncogenic process2,3. The first mutation that occurs would result in a germ line mutation which
would then be passed on to the somatic cells of the embryo. During mitosis, another mutation, a
“second hit”, occurs in a single cell. If these somatic mutations accumulate, an abrogation in the
tumour suppressor gene will occur3,4. Knudson came upon this discovery when studying
Retinoblastoma cells where he found that in a sporadic Retinoblastoma, if the two alleles are
wild type then two mutations will be required to cause disease. On the other hand, if the alleles
were heterozygous, then one mutation will be required to result in disease formation3,4. The gene
byproducts of tumour suppressors can be affected when the suppressor’s function is abrogated.
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A key pathway that regulates cellular growth and proliferation is the Mammalian Target
of Rapamycin (mTOR)5,6. One of the upstream regulators of mTOR is a heterodimer complex
called the Tuberous Sclerosis Complex (TSC). This heterodimer is made up of Tuberin, encoded
by the gene TSC2 and Hamartin encoded by the TSC1 gene6,7. Mutations that occur in these
tumour suppressor genes can lead to tumour formation. An example that has been well studied is
the disease Tuberous Sclerosis (TS). This disease is usually passed on by genetic inheritance
through parents that possess germ cell mutations. The transmission of TS can happen through
spontaneous genetic mutations called de novo mutations. Such spontaneous mutations occur
more frequently. Statistically, 60-70% of patients do not exhibit any genetic inheritance from
sporadically caused mutations7. Under circumstances where there is heterozygous inactivation
in either genes, TSC1 or TSC2, it will be inadequate to cause severe disease phenotypes in
patients7. Conversely, it is imperative that second hit somatic mutations are behind serious
disease manifestation to arise. These mutations depict Knudson’s Tumour Suppressor model2,8.
While the protein products of these genes work together it is known that mutations in the TSC2
gene are more frequent and result in more severe phenotypes than mutations occurring in the
TSC1 gene9.
The TSC2 gene is situated on chromosome 16p13.3 and constitutes of 42 exons overall
and 41 of them code for the protein, Tuberin8. TSC1 is found on chromosome 9q34 and
constitutes 23 exons

8,10

. The protein Tuberin has a molecular mass of 200 kDa, Hamartin is

smaller with a molecular mass of 130 kDa. Interestingly, the molecular mass of the TSC is
roughly 450 kDa which is bigger than Tuberin and Hamartin forming independently, implying
the presence of additional members of the complex are yet to be identified11,12. The TSC is
formed through Hamartin interacting with Tuberin at the N-terminus (Figure 1). Hamartin and
2

Tuberin interactions function to support and stabilize Tuberin by preventing Tuberin’s
degradation by HERC1 ubiquitin ligase13,11. The primary characterized functional domain of
Tuberin is the GTPase activating protein (GAP) domain residing in the C-terminal portion of the
protein.

Tuberin GAP function is directed toward the GTP binding protein Ras homolog

enriched in the brain (Rheb), which itself has GTPase activity and is responsible for negatively
regulating mTOR.

Figure 1. Tuberin Structure Showing the Functional Domains
Highlighted with a red box at amino acid (aa) 1-418 is the Hamartin binding domain, at aa 11011320 is the 14-3-3 binding region and the functional GAP domain is indicated at aa 1517-1672.
Two coiled-coil (cc) domains, a leucine zipper (LZ), and a calmodulin binding region (CaM) are
indicated as boxes on the diagram itself. Phosphorylation sites are indicated by a P with either
an inhibitory or activating modification and the primary kinase indicated above. Adapted from
Rosner et al. 20088.12

II.

TSC and mTOR Signalling

Tuberin and Hamartin are indispensible tumour suppressor proteins needed in controlling
cellular growth via the mTOR pathway6. Tuberin function is largely affected by post3

translational modifications occurring via nutrient signaling such as growth factors (ERK) and
insulin (PI3K/Akt) and direct sensing of ATP levels (AMPK)14,15 (Figure 1). These signals are
then transmitted specifically to the downstream effector mTOR or directly to the cell cycle
machinery to regulate cell size, proliferation, and protein synthesis6 (Figure 2).

Figure 2: mTOR Pathway
Cartoon depicting the links between the TSC (Tuberin and Hamartin) with the mTOR
pathway and cell cycle regulation. Upstream signaling from the insulin growth factor
receptor (IGF) is one representative feed from a nutrient pathway.

mTOR is a large protein and has a molecular mass of 289 kDa and belongs to the
superfamily phosphatidylinositol kinase-related kinase (PIKK)16. Based on research conducted
on yeast, Saccharomyces cerevisiae, the Target of Rapamycin (TOR) was discovered. TOR1 and
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TOR2 are the two major genes that form the TOR proteins. Researchers concurred that these two
genes have been known for their Rapamycin sensitivity; however, recent research has
demonstrated that TOR2 possesses Rapamycin insensitivity features. Being insensitive to the
drug, Rapamycin, TOR2 acts as a roadblock in decreasing TS symptoms17. In mTORC1,
mLST8 can bind to mTOR to facilitate its kinase activity. Also, mTOR can bind with rictor
(Rapamycin insensitive), and associate with SIN1 and mLST8 to form mTORC2 and preserve
its integrity17.12
mTOR is the downstream effector of PI3K/Akt signal transduction pathway. This pathway is
initiated when ligands or hormones bind to the IGF receptor on the cell membrane surface. Once
binding of the ligand to the receptor takes place, phosphorylation of PI3K instigates a regulation
cascade that creates a positive feedback loop amongst all the elements in the pathway6. If mTOR
is misregulated due to the mutation in TSC2 or TSC1, certain acute phenotypic manifestations
will be visible and diseases become dominant. Amongst these diseases are: Tuberous Sclerosis,
autism, and Alzheimer’s disease, etc.8. 12
Tuberin also directly regulates the cell cycle by enhancing the functional activity of p27, a
cyclin-dependent kinase (CDK) inhibitor. Previous studies had shown that Tuberin expression
levels in cells have a huge impact on the cytoplasmic or nuclear localization of p277. This
suggests that the CDK inhibitor, p27, works as a tumour suppressor by inhibiting CDK activity7
,12

. Tuberin is also capable of regulating mitotic onset binding directly to the mitotic cyclin,

Cyclin B1, and controlling the timing of the nuclear transport of the protein, a fundamental step
that triggers mitosis18. Collectively, Tuberin functions as a pivotal mechanism of translating
information about the nutrient status in a cell. When energy levels are low, Tuberin is regulated
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and inhibits growth and proliferation. Conversely, Tuberin is inactivated in situations of high
nutrient levels to permit growth and cell division18.

III.

Brain Development and Neurogenesis

Brain development.
The first stage of embryonic development from a blastula is gastrulation, or the
reorganization of cells into the three germ layers; ectoderm, mesoderm, and endoderm19,20,21.
Gastrulation is followed by organogenesis which is a stage initiated by the development of the
neural tube which is the structure from which the CNS originates21. Neural tube formation is
elicited by signals from a structure that arises from the mesoderm called the notochord21. The
CNS and the brain arise from the ectoderm20,21. Environmental signals inhibit neural specific
tissues from becoming other ectoderm structures such as the epidermis. Two critical signaling
pathways that dictate patterning of the neural plate, which acts as the foundation of the CNS and
arises from the ectoderm, are the Wnt pathway, responsible for CNS patterning, and the Bone
Morphogenic Protein (BMP) pathway22. During neurulation the cells located around the neural
plate undergo invagination and folding to form the neural tube22. The neural tube is characterized
by polarization alongside the ventral-dorsal axis23. The spinal neurons exist in the dorsal area of
the neural tube whereas the motor neurons are located in the ventral area where they receive
external signals19,23. The ventral pattern and dorsal pattern are induced by the notochord and
epidermis, respectively23. This patterning is critical for dictating the continued development of
the CNS as a whole and forming the spinal cord and the brain.

6

Neurogenesis.
Neurogenesis is the cell biology process by which different neural structures are formed
through the production of neurons and glial cells from a neural stem cell and underlying
progenitor cells24,19. The development of the human brain begins at the third week of gestation25.
However cell fate, or the concept of what the cells will become, is partly determined by the
polarity of the neural stem cell and the position by which it lies in the developing embryo. One
of the key processes in neural development is the process of neural induction that occurs at the
blastula stage. Throughout neural induction, cells found in the embryonic ectoderm are instigated
to differentiate and to specialize into cells that contribute to the overall formation of the CNS19,26.
Neural induction sets the stage for cells to take specific routes in response to external signals.
Throughout the developmental process the stem and progenitor cells will receive cues from the
changing environment to guide the differentiation decisions determining the number and type of
neural cells formed19. The two routes that cells can differentiate into are glial cells or neuronal
precursor cells. As the cell fate decision is being made, the cells become committed to a certain
type of cell which down the road will be differentiated into a neuron or a mature glial cell type 26.
The events that take place while the embryo is still developing are quite important due to the fact
that critical CNS structures are formed at the end of that period25.
The population of cells located in the wall of the developing neural tube, are
neuroepithelial cells which ultimately differentiate into different cell types such as neurons and
glial cells. As the process of neurogenesis proceeds, the cells within the neural tube undergo a
series of events that involves reorganization and rearrangement of the cells within the neural
tube27,23. This series of rearrangements allows the population of proliferating progenitor cells to
go through neural divisions either symmetrically or asymmetrically28. It is crucial that the
7

process of neural tube formation does not go wrong because any defects in this process will
cause neurological defects in the embryo such as Spina Bifida29. 1 in 2000 newborns experience
neural tube defects in the US29. Patterning of the neural tube is a result of environmental signals
that are secreted by certain molecules19,23,30. The ventral axis patterning is governed by Sonic
Hedgehog signaling which eventually leads to the expression of transcription factors that give
neural progenitor cells their integrity31. On the other hand, BMP and Wnt signaling pathways
govern the patterning of the dorsal region of the neural tube27,23,32. All in all, neurogenesis is a
crucial process throughout mammalian brain development. Furthermore, the activity of
neurogenesis is higher in regions of the brain like the cerebellum which regulates motor
control33.
Implications of Tuberin in neural development.
While not well-understood, Tuberin has been implicated in development. Floricel et al. have
conducted experiments that show when TSC2 is mutated in vivo, neurological development
especially in the brain is negatively affected34. They found that neurite outgrowth was inhibited
within the PC12 cell line34. Additionally, in a separate study by Choi et. al., they demonstrated
that axons that formed were disordered. This was mainly observed when TSC2 or TSC1 were
knocked down. In the absence of TSC2 or TSC1, axonal outgrowth increased in the cells. Under
conditions where these genes were overexpressed, axon formation was repressed35. Furthermore,
it has been demonstrated that the knockdown of TSC2 or TSC1 led to an increase in the size of
cells in the postmitotic neurons and dendritic spines36. Collectively, these findings imply the
intriguing possibility that Tuberin is important in the process of neural cell fate decisions.

8

IV.

A Brief Overview of Cerebellum Development

The cerebellum is a brain structure situated in the hindbrain specifically in the anterior
region37. It is responsible for regulating sensory-motor processes37. Of the vast majority of
neurons that make up the brain, about half of them are located in the cerebellum37,38. The
rudimentary structures of the cerebellum start forming at six weeks of embryonic development
within the human brain. CNS development begins very early in embryogenesis and it is the last
process to be completed after birth. On average, the brain is fully developed at 20 years of age.
In the cerebellum there is a heterogenous population of neurons. Pre-cerebellar neurons are
neurons found in the rhombic lip of the hind brain39. Through the process of nucleokinesis, these
cells migrate to designated places of the cerebellum by allowing their nucleus to move39,40.
Through several different processes of chemotactic agents, the movement of these cells is
guided39.
There are several layers of neuronal cells that make up the cerebellum and migrate to
designated locations termed the nuclear layer and the molecular layer41 (Figure 3). The
molecular layer is composed of Purkinje cells that are found between compact granule cells and
Purkinje cell dendrites41. The Purkinje cells are a group of the largest inhibitory GABAergic
neurons that process inhibitory information relayed to them by granule cell fibers. Granule cells
are located in the granular layer and they are classified as excitatory glutamatergic neurons. They
process inhibitory information received from Golgi neurons. Granule cells form axons that
penetrate to the molecular layer and make connections with dendrites of the Purkinje cells42.
Granule cell precursors usually reside in the External Germinal Layer (EGL) where they later
migrate from the rhombic lip to the pial surface during development. The EGL disappears when
the cerebellum is fully developed and the granule cells are found within the IGL43.
9

Figure 3. Illustration Depicting the Neuronal Cells that Make up the Cerebellum
Within the cerebellum, the neuronal cells reside in various layers such as the granule cell
layer, purkinje cell layer, and the molecular layer. Adapted from Tabata et al.44

V.

Stem Cells Have Distinctive Properties
A stem cell is present at various stages during development. It is an undifferentiated cell

that has the potential to differentiate or develop into different types of cells, tissues, and organs
in the body45. The stem cell population both creates an initial structure and it works as an internal
repair mechanism in the body by continuously dividing and replenishing damaged cells46. There
are two ways in which cells can divide; asymmetric cell division and symmetric cell division 47,48.
In asymmetric cell division, the parent stem cell divides into two daughter cells one of which is a
stem cell while the other is a non-stem cell that has the potential to specialize and differentiate
into a specific cell type such as a brain cell, or blood cell, etc. In a symmetric cell division, the
parent stem cell produces two new stem cells48,49,50. (Figure 4).
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Figure 4. Mechanisms of Stem Cell Division50
Illustration depicting the two different models of stem cell division. Stem cells can divide
asymmetrically, producing a daughter cell that is differentiated and another that is a stem cell. In
symmetric cell division the daughter cells produced are identical to the original parent cell.
Adapted from Shahrayari et. al. 2013.

In the asymmetric division model, it is believed that homeostasis is controlled at a single
cell level by having the parent cell produce one stem cell and one differentiated cell 48,51,46. One
problem that arises from the asymmetric division model is that in case of damage or injury, the
stem cell pool may exhaust the ability to self-renew. This problem is solved by the presence of
symmetric cell division model which controls and maintains homeostasis at a cell population
level as compared to a single cell level46.
The symmetric division model involves two different types of division which includes a
proliferation division and a differentiation division50,46. As mentioned above, proliferation leads
to the formation of two stem cells while differentiation gives rise to two differentiated
specialized cells from unspecialized progenitors46. The proliferation or differentiation division is
determined by certain signals or quos that are received by the stem cells from the surrounding
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environment. Proliferation and differentiation decisions must be controlled in order to maintain
homeostasis and balance control46. If these decisions are not controlled, stem cell expansion will
be tipped off balance. In addition, abnormal control of asymmetric division may lead to
formation of cancerous tumours due to build up of undifferentiated cells46,47. The main role of
stem cells in tissue is to maintain homeostasis through its major properties; differentiation and
self-renewal. Disease can be a serious result of fluctuations in the balance of such stem cell
populations50.
To classify a cell as “stem” cell, it must possess the two important stem cell
characteristics. The first characteristic is that the cell is unspecialized45. This feature means that
these cells are able to continuously divide and self-renew52. The second feature of stem cells is
that they are able to become committed and specialize into specific types of cells under certain
situations physiologically and experimentally52, 45.
Stem cells are divided into two main classes; embryonic stem cells as well as adult stem
cells45. An embryonic stem cell forms when the fertilized egg divides. These cells are present in
humans at the first 3-5 days of development at the blastocyst stage45. Cells at this stage are the
ones necessary to give rise to the organism as a whole. Adult stem cells are those that are found
in already developed tissues45,48. The main task of these cells is to repair damaged tissue. Adult
stem cells work to replenish specialized cells that are dead46. The brain, bone marrow, blood,
muscle, and skin, are the tissues with the most work done on adult stem cells45,46.
The existence of adult neural stem cells was a topic of much debate until a finding by
Nottebohm demonstrated that neurogenesis exists in the adult brain of vertebrates53. Neural stem
cells are stem cells that are found within the CNS which possess the ability of self renewal54.
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Mammalian neural stem cells were first isolated by Reynolds and Weiss in 199255. In their
studies, Reynolds and Weis investigated whether cells isolated from the stratium and grown in
culture were able to proliferate and divide in the absence of the epidermal grow factor (EGF).
These researchers have concluded that in order to promote the growth and proliferation of
isolated cells either from an adult or embryonic mouse brain sample, EGF is required. EGF
allows for the formation of free floating spheres which were eventually called “neurospheres”.
Neurospheres are composed mainly of glia and neuron cells55. These spheres also express the
neural stem cell marker, Nestin56. Reynolds et al. have also confirmed the stem cell identity of
the neurospheres by conducting experiments demonstrating that a neurosphere can form from a
single cell even when the neurospheres are dissociated55. This neural cell isolation was achieved
by building on information and discoveries made previously in 1983 by a group of researchers.
Raff and colleagues discovered a type of cell that has the capacity to differentiate into a fibrous
astrocyte and an oligodendrocyte57. This cell was derived from the optic nerve of a rat that was 7
days old. Their findings suggested that from a single glial progenitor cell in vitro, two different
types of cells were able to form57. Being able to isolate neural stem cells and producing other cell
types in culture can aid in contributing to finding a cure in patients suffering from neurological
disorders.
Since the discovery by Reynolds and Weiss, many researchers have begun studying
mammalian adult neural stem cells. In 1993, Luskin and colleagues were able to report that cells
in the adult subventricular zone (SVZ), exhibited continuous proliferation which in turn led to
the production of neurons in the olfactory bulb58. This suggests that within the SVZ there is a
population of neural progenitor cells that is continuously proliferating. Furthermore, the
ependymal region of the brain has also been shown to possess characteristics of neural cells.
13

Researchers have proved that ependymal cells are stem cells because they elicit neuron
production when the CNS is exposed to injury53.
The first neural stem cell extraction conditions characterized neurosphere assay as a
method of culturing and retaining stem cell characteristics55. This assay also began to teach a lot
about the conditions that maintain stemness in the brain as the neurospheres must be provided
with specific media and given necessary growth supplements55. For neural stem cells fibroblast
growth factor (FGF) and EGF are important in maintaining stemness. In addition, the nerve
growth factor (NGF) is needed to aid in producing neurons55. With today’s technology and
laboratory techniques cells can be extracted and cultured from nearly any region of the adult
vertebrate brain.
Among the different factors like FGF and EGF that have proven important in dictating
the stemness of the neural stem cell population, the Notch pathway plays a role in regulating cell
fate decisions and cell self-renewal59. The Notch pathway is highly conserved and involved in
important cellular decisions such as proliferation and differentiation especially during
embryogenesis and CNS formation59,60. In the brain, the neural progenitor cell population is
sustained through the Notch pathway59. This pathway is composed of 4 protein homologues;
Notch1, Notch2, Notch3, and Notch4 that interact with the Notch receptor along with other
ligands that start a cascade of proteolytic cleavage events that result in Notch translocation into
the nucleus of the cell where interactions with downstream effectors begins to control the cell
proliferation, differentiation, and cell fate decisions59,60. Tuberin is involved in the Notch
pathway as an upstream effector61. In a study conducted by Ma et. al. in 2010, it was shown that
the mTOR pathway can be linked to an upregulation of the Notch pathway61,62. Some of their
findings revealed that when mTOR activity is increased, cell differentiation was impeded. To
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support the fact that when mTOR is hyperactive it leads to Notch upregulation, they proved that
in mouse embryonic fibroblasts (MEFs) with hyperactive mTOR, Jagged1, the Notch ligand, was
also found at increasing levels61. Furthermore, experiments performed to inhibit the Notch
pathway were found to abolish tumour formation in the cells where mTOR was active61.
Studying stem cells and their ability to differentiate into specific cell types is critical.
Stem cells can provide scientists with some insight into how to cure certain diseases by
investigating how these cells contribute to development. Overtime, research findings can
contribute to curing diseases such as diabetes, neurological diseases, burns, etc. Studying stem
cells can provide limitless opportunities for healing disease.
VI.

Brain Tumours and the Cancer Stem Cell Model

The cancer stem cell (CSC) hierarchal model proposes that a subpopulation of cells existing
in the tumour cell mass is capable of driving tumour progression. As a result of the cells’ ability
to self-renew and differentiate, this subpopulation of cells leads to the regeneration of the cancer
causing cells leading to tumourigenesis63,64. On the other hand, the stochastic tumour model
hypothesizes that within a tumour, all the cells possess tumorigenic properties or can be
transformed to become tumorigenic64,65. There is evidence to support that both models may exist,
and indeed some cases where combinations of the two may co-occur, but certainly there is strong
evidence to support that some tumours arise only from a distinct population of cells that possess
stem cell properties63,65. Some researchers refer to these cells as ‘tumour-initiating cells (TIC)’
while others continue to use the more controversial CSC term. These TIC/CSCs have certain
properties which include self-renewal and differentiation into specific tissue cells66, 64. In 1994,
John Dick, a Canadian researcher, was one of the first scientists to discover the presence of CSCs
in certain leukemia models. In his study, he demonstrated using severe combined
15

immunodeficient mouse model, that cancer cells isolated using cell surface markers that express
a CD34+ CD38-, were able to form tumours when introduced into the mice blood system. These
tumours were representative of the tumour heterogeneity seen in patients with acute myeloid
leukemia67.
CSCs can lead to the formation of aggressive malignant tumours in the brain. One form
of cancer that follows this model is glioblastoma multiforme (GBM). These tumours generally
originate from neural stem cells located within the brain68,69. GBM usually occurs as a result of a
multitude of mutations and can occur both during childhood and during adulthood. The diversity
of mutations in this tumour makes the cancer causing cells a challenge to target with
chemotherapy70,71,72. It is believed that the neural stem cells that are the origin of this tumour are
located in the SVZ of the brain. In previous studies, cancer cells were isolated from the tumours
in GBM71. These tumour cells were able to self renew and produce more tumours which makes
this disease a recurrent disease even when exposed to conventional therapy72.
VII.

Medulloblastoma: Childhood Cancer

Medulloblastoma (MB) is the most common fast-growing neuroectodermal pediatric
malignant brain tumours and is the number one cause of mortality in children diagnosed with
brain cancer73,74. According to the American Brain Tumor Association, 400 patients are
diagnosed with MB each year with the majority of patients being children up to 10 years of
age74. Some of the symptoms that are associated with Medulloblastoma are; lack of co-ordination
and balance, vomiting, headaches, behavioural changes, and double vision73,74. Some treatments
have been developed to alleviate these symptoms in young children73,74.
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One of the most effective ways to manage tumours is tissue re-sectioning through surgery
and the removal of the tumour mass73,74,75. Although surgery aims at removing most of the
cancerous mass, there is a high risk of recurrence through the cerebral spinal fluid (CSF)75,76.
The CSF is one of the pathways through which tumour cells can spread; therefore, it is important
to keep track of the nature of the cells that are found in the CSF76. Chemotherapy and radiation
that target the brain and spinal cord are standard of care and can shrink the tumour mass but are
currently not curative.
VIII. MB Neuropathology:
MB is classified as a Primitive Neuroectodermal Tumour (PNET)77,78. These embryonal
tumours are characterized by immature and undifferentiated neural tissue78. MB tumours are
found in the cerebellum and the cell of origin is believed to be granule neuron precursors
(CGNPs) located in the EGL78,79,73,77. The EGL is naturally composed of different types of cells
mainly including precursor cells. To make it up to the external layer of the cerebellum, these
cells migrate to the surface. Once they reach the surface of the cerebellum, the cells differentiate
by going through cell division stages78. To form the granular layer, the neurons move inwards. In
humans, the EGL, remains present in the cerebellum until 2 years of age78,42. The purkinje cells
as well as the cerebellar nuclei arise from the subependymal matrix around the fourth ventricle.
MB tumours are solid and distinctive78. Histologically, cells appear oval and small with little
cytoplasmic to nuclear ratio78. In a study focusing on 21 MB patients, the differentiation capacity
of the cells from 20 samples that were categorized under classic MB, were studied using glial
fibrillary acidic protein (GFAP), neurofilaments (NF), S-100 protein (S-100P), and neuron
specific enolase (NSE)80. The findings from this study showed that the majority of the cells were
positive for NSE which is a nonspecific marker for embryonic cells, neuroblasts80. This suggests
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that neuroglial cells within the MB tumour are actually undergoing differentiation 80. The tumour
cells are heterogeneous and may contain differentiated cells where the majority is expected to be
undifferentiated.
Generally, MB emerges due to genetic mutations that occur in the pathways that are
involved in cerebellum formation which lead to developing tumour cells from stem cells. In
2011, a group of researchers studied primary MB samples. Using techniques such as genome
profiling in combination with bioinformatics approach, scientists were able to divide MB into
four distinct subgroups based on several factors. These factors and categorization was based on
the metastatic status of the tumour, DNA copy number aberrations, and histology81.
Classification of the tumors was also based on age groups. MB is categorized into four different
subgroups; WNT, Sonic Hedgehog (SHH), Group 3, and Group 481. Classifying MB into the four
different subgroups allows researchers to investigate specific characteristics of cells in each
subtype and propose several targeted therapies particular to each subtype. To date, the WNT and
SHH pathways are more heavily and well studied compared to Group 3 and Group 4
subtypes81,82,83.
MB categorized into the WNT subgroup, is a rarely occurring tumor75,83,84. The Wnt
pathway is an essential pathway that is activated during embryogenesis75,84. During development
Wnt acts to regulate extremely important processes such as cell fate, embryo patterning,
proliferation and cell growth. Protein interactions in the Wnt pathway are essential for tightly
regulated cell to cell communication. Wnt misregulation or mutations are implicated in diseases
such as cancer75. Studying what genetic mutations can lead to Wnt malfunction can be
implicated in stem cell fate. The primary receptors found in the Wnt pathway are Frizzled (Fz)
and LRP 84. In a normal cell, Wnt signalling is usually inactive, a destruction complex made up
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of Axin and APC secure the transcriptional regulator β-catenin and target it for ubiquitination
and proteolytic degradation. Wnt pathway is activated when a Wnt ligand binds to Fz and LRP, a
membrane receptor84,. The binding processes induces the activation of Dishevelled (Dsh) which
leads to the disintegration of the destruction complex causing β-catenin levels to increase in the
cytosol and nucleus. When high levels of β-catenin are present, β-catenin accumulates in the
cytosol and the nucleus as a result of the lack of degradation by proteosomes84,85. In the nucleus,
β-catenin binds to the TCF/LEF transcription factor thereby changing the role that TCF/ LEF
transcription factor plays as a repressor. Conversely, TCF/ LEF transcription factor activates
RNA polymerase that prompts gene transcription. A malfunction in this system that
inappropriately activates the Wnt pathway by a Wnt signal can lead to a mutation in one of the
few genes that form the destruction complex84,86.
Another MB subtype is driven by the Shh pathway75,82. SHH is the gene that encodes for
the protein Shh, a morphogen75. The Shh pathway is inactivated by the receptor Patched (Ptch)
and in turn Smoothened (Smo), the signaling receptor, gets suppressed by Ptch, thereby
inhibiting the transcription factor, Gli and the downstream signaling cascade75,87. When the Shh
ligand is present it binds to Ptch at the cell surface which leads to its degradation of Ptch 75,87.
This results in Smo moving from the intracellular vesicle to the cell surface to initiate Shh
signaling and Gli gets activated which can then regulate gene expression75,88,87. Historically, the
hedgehog gene was identified in 1980 in Drosophila melanogaster embryo89. Researchers
performed genetic screening to identify embryonic lethal loci in Drosophila89. They looked for
genes that are mutated and influence the segment polarity. One of those genes was the one that
encodes for Shh. Shh is responsible for establishing the patterning during embryonic
development89. It is important in creating the midline of the spinal cord, the brain, and the overall
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body pattern etc75,89. In addition Shh is essential for the development of the CNS as a whole90. It
follows that mutations in SHH, can lead to severe neurological diseases and congenital defects
such as holoprosencephaly (HPE) which results due to an aberration in Shh and incapability of
the two brain hemispheres and the eyes to develop normally90.
Shh affects signaling in the neural precursor cells (CGNPs) which are believed to be the
cells of origin of the childhood cancer MB91. Interestingly, mutations in TSC2 can cooperate with
the Shh pathway to lead to formation of cancerous tumours88. In a study performed by Bhatia et
al. in 2009, researchers used a transgenic mouse model that was dominant negative for TSC2
(TSC2-RGΔ)88. The lack of Tuberin resulted in aberrant proliferation of CGNPs as well as
cellular growth was increased indicating abnormalities in cerebellar development. Importantly,
the TSC2-null/transgenic mouse model had enhanced susceptibility to the initiation of SHH
subtype of MB. Characterization demonstrated that there was an increased number of neural
precursor cells along with an increase in mTOR signaling and an inhibition of p27 and GSK3α/β
activity 75,88.
IX.

Hypothesis and Objectives
I hypothesize that Tuberin protein levels will vary throughout the brain, with levels and

activity being higher in regions of peak neurogenesis activity. Tuberin is crucial for brain
development and neural cell differentiation. The tumour suppressor protein, Tuberin, halts
the cell cycle to allow for asymmetric division and differentiation of cells; therefore, I
hypothesize that Tuberin levels are lower in differentiating cells as compared to progenitor
cells and it serves to regulate stem cell differentiation. It is important to determine the normal
role of Tuberin in neural cell fate; proliferation and differentiation during early development.
In addition, I hypothesize that Tuberin plays a critical role in the self-renewal of CSC
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populations within MB.
Objectives:
1. Determine Tuberin Protein Levels During Early Brain Development
Immunohistochemistry DAB staining will be performed on specific brain regions critical
for neurological development, such as the choroid plexus and the purkinje cell layer, and
Tuberin protein levels will be quantified and compared at ED 14.5 and ED 16.5.
2. Identify the Importance of Tuberin During Cerebellum Formation and Cell Fate
Determination using Primary Cerebellum Cells
I will optimize the isolation, culturing and differentiation of primary cerebellum cells
from Balb/C mouse. I will measure changes in Tuberin mRNA through differentiation
and optimize neurosphere experiments to begin to determine the importance of Tuberin in
neural stem cell decisions in the cerebellum.
3. Elucidate the Role of Tuberin in MB CSC Population.
Tuberin levels will be manipulated in a MB cell line and properties of the CSC
population studied using neurosphere assays and cell surface markers using flow
cytometry.
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MATERIALS AND METHODS
I.

Animals and Breeding

BALB/c mice (Stock number 000651), were purchased from Charles River Laboratories. The
mice were kept in the animal care facility at University of Windsor. The experimental procedures
set by the University of Windsor animal care committee were followed as directed in AUPP #
12-18. BALB/c mice were bred in the animal care facility and the F1 generation was obtained.
Mice were euthanized at embryonic day (ED) 14.5 and 16.5 using the CO2 asphyxiation
chamber.
All BALB/c mice were housed in the same animal care facility room. Mice were maintained
under a 12 hour light 12 hour dark cycle. Female mice were placed in cages separate from the
male mice. To increase the chances of the female’s pregnancy, mouse shavings from the
female’s cage were introduced into the male’s cage a day before the scheduled breeding date. For
embryonic time points females were separated and checked for a copulatory plug the next
morning; denoting day 0 of pregnancy.
To acquire postnatal brain samples, the mice were kept together for three nights to ensure the
chances of successful breeding. The gestation period for the mice was about 21 days. The mice
were checked and monitored throughout the 21 gestation days. Once the pups were born, that
day was assigned to be postnatal day 192.
II.

Tissue Samples Dissection and Fixation

Mice were sacrificed in the most humane way possible to obtain samples. For postnatal
samples, mice were placed in a CO2 chamber for euthanasia. The CO2 cylinder is set to 4 psi.
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The mice were left in the chamber for 3-6 minutes as per the guidelines from the University of
Windsor Animal Care and Use Committee, AUPP#12-18.
Prenatal brain samples were obtained by extraction of the embryos following euthanization
of the mother. For both embryonic and postnatal brain samples, the brain was placed in 4%
paraformaldehyde PFA solution overnight. Extra embryonic tissues were then removed and
embryos were placed in a fresh PFA solution for another night or until the expected tissue
rigidity was achieved. Sequentially, the samples are moved through a sucrose gradient starting
with a 20% sucrose gradient (200 mL High Purity Water and 40g sucrose) moving up to 30%
sucrose gradient (200mL High Purity Water 60g sucrose). The tissue was left in each gradient
overnight at 4◦C. Once one observes that the brains sunk to the bottom of the tube, the gradient
could be changed and the brains are cryoprotected.
III.

Tissue Sectioning

The heads were submerged in Shandon M-1 Embedding Matrix (Thermo Electron Corp.;
#1310) and then placed in a vacuum for 20 minutes at 10mmHg for fixation purposes. The tissue
in matrix was then frozen at -20◦C for about 30 minutes and at a temperature of -18◦C. Brain
tissue was sectioned at 30 μm in the sagittal plane under cold/ freezing conditions using a
cryostat (Leica cm3050s). For the postnatal time points, the brain was sectioned in the sagittal
plane at 18 μm thickness. Sections were mounted using permount mounting media (Fischer
Chemicals; #SP15-100) onto Superfrost Plus slides and stored at -80◦C.
IV.

Immunohistochemistry (IHC): DAB Staining

Slides containing tissue sections were left at room temperature for 10 minutes to ensure the
tissue adhered properly to the slide. The slides were then incubated in 0.3% H2O2 for 30 minutes
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to block endogenous peroxidase activity. Slides were washed with 1X PBS for 5 minutes and
then incubated at room temperature with diluted blocking serum, which prevents non-specific
binding, for 20 minutes. The primary antibody, rabbit anti-Tuberin polyclonal antibody (Santa
Cruz; #sc-893) was administered to the sections on the slides. The slides were then left at 26◦C in
a humidity chamber for approximately one hour or left at 4◦C overnight. The slides were washed
again with 1X PBS for 10 minutes. The secondary antibody was administered to the slides at
room temperature for one hour. This was followed by washing in 1X PBS for 10 minutes. The
negative control slides were lacking the primary antibody.
At the final stages of staining, DAB, 3,3-Diaminobenzidine substrate solution (Vector
Laboratories, PK 61010) with H2O2 was used to incubate the slides after the wash in 1X PBS
solution for about 30 seconds to 1 minute. Once a brown colour appeared, the slide was placed in
1X PBS in order to stop the reaction and to obtain adequate staining. Sequentially, the sections
were dehydrated by submerging them through an ethanol gradient of 70% ethanol, 95% ethanol,
and 100% ethanol; followed by submersion in xylene to clear the tissue samples. The slides were
placed in each gradient for approximately 10 minutes. Slides were mounted using Permount and
then coverslips were applied to the slides.
Leica CTR 6500 microscope was used to obtain pictures of the stained sections using the
DFC 425 digital colour camera. Paxinos and Franklin’s mouse brain atlas was used to identify
anatomical features of the brain93. The two main regions that were examined for embryonic time
points ED 14.5 and ED 16.5, were the purkinje cell layer, and choroid plexus. The cerebellum
was the structure of main focus in the postnatal brain samples. The pictures of the regions were
taken at the following objectives; 2.5x, 10x, 20x and 40 x.
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V.

Immunohistochemistry (IHC): Quantification and Analysis

Three sections of each sample were quantified using the program ImageJ. A gradient of black
and white was used to calibrate the program with white selected as the background colour on the
‘step tablet’ with a range of 0-250, 250 therefore representing the lightest staining.
Representative sections were selected for the background (white region – designated as 250), and
the darkest stained region (set to 0). Specific brain regions were compared on this scale by using
the “free hand tool” to manually outline the region in the brain. Values that were obtained from
control slides were subtracted from the slides containing secondary antibody. This difference
reflects the difference in optic density between the control stained sections and the primary
antibody stained sections.
VI.

Immunofluorescence and Analysis

Sections were washed with 1X PBS for 5 minutes. Excess PBS was dried with kim wipes and
the sections were outlined with a grease pen to prevent the antibodies from mixing and
overflowing the sections. A solution consisting of 0.2% Triton diluted in 1X PBS was used to
wash the sections for 5 minutes in order to permeabilize the tissue. Following this, the slides
were washed in 1X PBS for 5 minutes. Consequently, the slides were incubated in LAP blocker
(500 μL of Triton x-100, 0.75g glycine, 1.25 mL FBS, up to 50 mL 1X PBS) for 15 minutes
before applying the primary antibodies to the sections in order to prevent nonspecific binding of
antibodies (Muller et al, 2009). After taking off the excess LAP blocker, the rabbit anti-Tuberin
polyclonal antibody (Santa Cruz Biotechnology; # sc-893) was diluted in the blocking serum
with 1:250 μL ratio. The sections were left to incubate in the primary antibody at 4°C overnight.
The control slides were treated only with the primary antibody and cover slipped the same day.
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The next day, 1X PBS was used to wash the sections from primary antibody residue three
times, 5 minutes each. Then secondary antibody was applied to the sections for 30 minutes. The
secondary antibody consisted of 500 μL of LAP blocking serum, 1 μL of Alexa Fluor-488 goat
anti-Rabbit dye (ThermoFischer Scientific; #1705869) and 1 μL of Hoechst (ThemoFischer
Scientific; #62249). Due to Hoechst solution’s sensitivity to light, sections and secondary
antibody, Texas Red goat anti-mouse (Life Technologies; 1666400) were covered in aluminum
foil at all times. The slides were washed again with 1X PBS and cover slipped with anti-fade
mounting solution. The light sensitive slides were then stored in an opaque box .
Leica CTR 6500 microscope was used to obtain pictures of the stained sections using the
FX360 digital colour camera for better resolution. Leica Application Suite (LAS) AF was the
software that was utilized to view fluorescent images. As previously mentioned, the two main
regions that were examined were the purkinje cell layer, the choroid plexus, and the cerebellum.
The DAPI filter was used to look at the Hoescht stained nuclei of the cells. The GFP filter was
used to detect the green dye, Alexa Fluor 488, for the Tuberin expression for
immunofluorescence staining. Sections were imaged at 2.5X, 10X, 20X and 40X objectives.
VII.

Primary cerebellum Tissue and Cell Extraction from Balb/c Mice

To begin the tissue extraction procedure, the working station must be sterilized and the
dissection equipment must be autoclaved. The mice were first euthanized using a CO2 chamber.
The mouse head was swabbed with 95% ethanol and an incision across the midline of the skin
and along the skull was made. In order to be able to expose the skull, the skin was pulled and cut
underneath the ears to ease the process of tissue extraction. The skull was peeled off with sharp
point forceps carefully without damaging the brain tissue under it. All connections to the brain
such as the spinal cord and blood vessels were cut by picking up the brain from the base with
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forceps. The brain was placed in a 60mm cell culture tissue dish (Sarstedt AG & Co.; #83.1801)
and washed in DMEM media (Sigma Aldrich; # D5796) containing 3% penicillin and
streptomycin (Gibco; #1540) for 2 minutes on a shaker.
All steps following this were carried on in a laminar flow hood. In order to extract the cells,
the cerebellum tissue must be diced into 1mm3 pieces using a scalpel blade no. 11. Once, the
tissue was minced, it was transferred into a 15mL round bottom tube with DMEM media
(Sigma-Aldrich; #D5796). The tissue was triturated using a Pasteur pipette by pipetting up and
down gently and cells were spun at 250g for 1 min. The supernatant was removed and 1 mL of
0.05% Trypsin (HyClone; #SH3023601) was added. The tube containing the cells was placed in
a 37°C water-bath for 5 minutes. The cells were triturated again and DMEM media was added to
inactivate the digestive ability of the Trypsin. The cells were centrifuged at 250g for 5 min and
the supernatant was removed, and 2 mL media consisting of 10% FBS was added and the tube
was spun for 5 min at 500g. The supernatant was discarded and the cells were dissociated into
Neurobasal media (Thermo Fischer Scientific; # 21103-049) with B27 (Thermo Fischer
Scientific; # B27), 20ng/ml EGF, and 10ng/ml FGF supplements (Thermo Fischer Scientific; #
B27). The cells were then plated onto low adherent 6-well cell culture plates (Corning; #3471) at
a density of 5 x 104. The cells were monitored and media was replenished every three days. Once
the cells start forming neurospheres, they can be collected and plated on adherent 6-well
attachment plates and can be used for differentiation assay experiments. The neurosphere
formation assay protocol was previously established by Pacey et al. (2006).
VIII. Cell Culture: Primary Cerebellum Cells Assays
Primary cerebellum cells were maintained in serum free Neurobasal Medium supplemented
with B27, 20ng/ml EGF (Gibco; #12483) and 10ng/ml EGF (Sigma; #1540). The cells were
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seeded at 5x104 cells per well in an ultra low attachment 6-well plate (Corning; #3471). Cells
were incubated at 37°C in 5% CO2. Every 5-10 days the primary neurospheres that formed were
subcultured using 1 mL 0.05% Trypsin to detach the cells (HyClone; #SH3023601). Once the
subcultured primary sphere cells were needed for differentiation assays, the cells were provided
with medium supplemented with 2% Fetal Bovine Serum (FBS) (Gibco; #12483). To harvest
primary, and secondary neurospheres, the cells were seeded at 10000 cells per well in the ultralow attachment plates. Fresh media was added to the plate every 2-3 days to enrich the most
stem-like population of cells. All samples were collected by centrifugation at 1000 rpm for 5
min.
IX.

Cell Culture: DAOY Cell Line Neurosphere Assays

The DAOY cells were seeded at 5x106 cells per well in a 10 cm cell culture plate. They were
incubated at 37°C in 5% CO2 and maintained in EMEM media supplemented with 10% FBS and
1% penicillin and streptomycin until they reached 80% confluency. To grow cells in
neurospheres, cells were subcultured onto low adherent 6-well plates and supplied with
neurobasal media and growth factors B27, 20ng/ mL FGF, and 10ng/ mL EGF to enhance
neurosphere formation. Once neursopheres were formed, they were subcultured into secondary
neurospheres using 0.1 mM EDTA to dissociate the cells. A subset of the DAOY cells were
treated with 250 ng/mL of Rapamycin and were then grown into neurospheres. The neurosphere
numbers were counted using the Leica M205 FA fluorescence stereo microscope.
X.

Lentivirus Production

Tuberin knock-down vector (pLKO.1. shTSC2) was obtained through (Addgene; # 15478).
The production of the VSV-F pseudo typed lentivirus was executed by a HEK293 LentiX cells
transient transfection. The transfection was performed with the specific plasmid along with
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pMDG, pMDL2, and pRSV packaging plasmids with the aid of Polyethylenimine (PEI) (Sigma
Aldrich, # 408719) in a DNA to PEI ratio of 1:3. This was followed by incubation in 5% CO 2 at
37°C for 5 hours. The following day, virus collection was performed and through
ultracentrifugation, the collected virus was concentrated at 4ºC for 3 hours. Viral titer
determination was done by 293T cells transduction. This process was followed by flow
cytometry analysis of eGFP protein expression at 72 hours after transduction. The titred virus
was filter sterilized and stored at -80°C.
XI.

Cell Culture: DAOY Cell Line Tuberin knock down

For Tuberin knock down experiments using DAOY cell line, the cells were subcultured in
96- well plates with 100 μl EMEM media without antibiotics or serum overnight and 10μg/mL of
polybrene (Santa Cruz sc-134220) was added. 1 μl of shTSC2 virus was then added per well. A
subset of cells were treated in the same way with the scrambled sequence vector, PLKO.1, as a
control. The following day, the media was removed and cells were washed with 1X PBS and
then fresh media containing 2 μg/ mL puromycin (Sigma-Aldrich; #P8833) was added in order to
select for cells that have been successfully infected. After giving the cells 1-2 days recovery
time; they were then used for experimental assays.
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Table 1: Established Cell Lines
Cell line

Source

Disease

Primary Cerebellum Primary Extraction None
Cells

Tissue
Brain/ cerebellum

from PN 4 Mouse
Cerebellum.

DAOY- HTB-186

ATCC

Desmoplastic

Brain/ cerebellum

Medulloblastoma

XII.

Cell Surface Marker Analysis: Flow Cytometry

As previously described, DAOY cells were treated, cultured and collected. Cells were
centrifuged and cell pellets were collected to prepare for flow cytometry experiments. For every
sample, 5x106 cells were stained with rabbit anti-Tuberin polyclonal primary antibody and
Alexa488 rabbit secondary antibody. In addition, cells were labeled for CD133 using CD133/
Allophycocyanin (APC) antibody (eBioscience; #17-1338-42). Cells were left to incubate on ice
for 45 min in the dark.

Some samples were double labeled with TSC2 and CD133. BD

Biosciences Flow Cytometry Transcription Factor Set was used to perform the staining
procedure (Pharmingen; # 562574). Once the incubation period was over, the cells were spun at
250g for 5 minutes, washed 2 times with PBS. Cold 1xPBS is used to re-suspend the cell pellets.
Samples were analyzed using the BD LSR Fortessa X-20 cell Analyzer.
XIII.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

RNA was extracted from samples using an RNeasy Extraction Plus Mini Kit (Qiagen;
#74134) as per manufacturer’s protocol. A NanoDrop Spectrophotometer (ND-1000 software
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version 3.3.0, Thermo Scientific) was used to measure the concentration and check the purity of
the obtained samples. The obtained RNA samples were stored at -80ºC until needed for cDNA
synthesis. Superscript II reverse transcriptase (Invitrogen; #100004925) was used to convert
RNA to cDNA. ABI Viia7 thermocycler (Applied Biosystems; #278880504) was used to carry
out qrt-PCR with Fast SYBR green to detect gene expression levels. The reaction was run for the
length of 45 cycles. The primers that were used were specific for each cell type with GAPDH
being the internal control at a concentration of 5μM. Specific primers are listed in Table 2 and
Table 3. Obtained PCR results were reported as CT values that are relative to GAPDH. Further
data analysis was carried out using Microsoft Excel and the final results are represented as log10
RQ or RQ Values.
Table 2: Mouse Oligonucleotide Primers
Forward Primer (5’-3’)

Reverse Primer (5’-3’)

GAPDH

GCACCGTCAAGGCTGAGAAC

GGATCTCGCTCCTGGAAGATG

TSC2

TTGTGAGGAGGTTATGGCCATT

GCAGCTGAACTTCATCTCTGTTGTAG

Nestin

ACCTATGTCTGAGGCTCCCTATCCTA ACCTATGTCTGAGGCTCCCTATCCTA

Mouse
Gene
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Table 3: Human Oligonucleotide Primers
Human Gene

Forward Primer (5’-3’)

Reverse Primer (5’-3’)

GAPDH

GCACCGTCAAGGCTGAGAAC

GGATCTCGCTCCTGGAAGATG

TSC2

GAGAGGAGCCGTGTTTTTTGTG

GACATGCCATGGCCTGGTA

CD133

CAATGACCCTCTGTGCTTGGT

GTGGAAGCTGCCTCAGTTCAG

Nestin

AGAGGGGAATTCCTGGAG

CTGAGGACCAGGACTCTCTA
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RESULTS
I.

Tuberin Protein Levels Vary Across Different Regions of the Mammalian Brain
To begin to determine when and where Tuberin protein is expressed across the brain a

specific focus on regions related to cerebellum development and general stemness
characteristics in the brain were investigated. Brain regions such as the olfactory bulb and
cerebral cortex were quantified and compared to the purkinje cell layer and choroid plexus,
which are the two regions of interest (Figure 5 A, B). These regions actively undergo
neurogenesis during embryonic development. Tuberin protein levels in each region were
compared at ED 14.5, and ED 16.5, respectively. The brain tissue was sectioned in the
sagittal plane and was treated with Tuberin primary antibody and DAB stain using
Immunohistochemistry technique (Figure 5 C, D). The levels of Tuberin expression seemed
to vary throughout the brain regions.
To determine how levels of Tuberin change over different time points in different regions
of the brain we first compared the trend of expression in the cerebral cortex (Figure 6).
Tuberin protein level intensities between the cerebral cortex at ED 14.5 and ED16.5 were not
significantly different hence the cerebral cortex represents a good control between these time
points (Figure 6A-C). As seen with the cerebral cortex, there was no significant change in
Tuberin protein levels in the olfactory bulb between ED 14.5 and ED 16.5 (Figure 7A-C).
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Figure 5. Tuberin Protein Levels at ED 14.5 and ED 16.5 in Different Regions of the Brain.
Immunohistochemistry was performed using Tuberin primary antibody. (A) A control image of
the full brain lacking the primary antibody. (B) Full brain image at 2.5x objective showing all the
brain regions; Purkinje Cell layer (PCL), Choroid Plexus (CP), and Cerebral Cortex (CC). Scale
bar 1mm (C) & (D) Tuberin protein levels at ED 14.5 and ED 16.5. The y-axis represents the
difference in optic density of the DAB stain which ranges from 0-250 with 0 value representing
the lighter DAB stain. The x-axis shows the brain regions; Purkinje Cell Layer, Choroid Plexus,
Olfactory bulb, and Cerebral Cortex, that were analyzed.
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Figure 6. Depiction of Tuberin Protein Levels at ED 14.5 and ED 16.5 in the Cerebral
Cortex.
Immunohistochemistry was performed using Tuberin primary antibody. (A) A control image of
the cerebral cortex lacking the primary antibody at ED 14.5 and ED 16.5 at 10x objective
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showing scale bar 200µm. (B) Image of cerebral cortex treated with Tuberin primary antibody at
ED 14.5 and ED 16.5. (C) Tuberin protein levels quantified at ED 14.5 and ED 16.5. The y-axis
represents the difference in optic density of the DAB stain ranging from 0-250 with 0 value
representing the lighter DAB stain. The error bars represent the SEM over 9 (N=9) individual
experiments. Statistical analysis was performed using single factor ANOVA. p> 0.05.

Figure 7. Tuberin Protein Levels at ED 14.5 and ED 16.5 in the Olfactory Bulb.
Immunohistochemistry was performed using Tuberin primary antibody. (A) A control image of
the cerebral cortex lacking the primary antibody at ED 14.5 and ED 16.5 at 10x objective
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showing scale bar 200µm. (B) Image of cerebral cortex treated with Tuberin primary antibody at
ED 14.5 and ED 16.5. (C) Tuberin protein levels quantified at ED 14.5 and ED 16.5. The y-axis
represents the difference in optic density of the DAB stain ranging from 0-250 with 0 value
representing the lighter DAB stain. The error bars represent the SEM over 9 (N=9) individual
experiments. Statistical analysis was performed using single factor ANOVA. p> 0.05.

Tuberin Protein Levels are Regulated in Certain Regions of the Brain
The choroid plexus and purkinje cell layer are brain regions that mark the beginning of the
formation of the cerebellum during embryonic development. The choroid plexus was examined
to assess Tuberin protein levels. The choroid plexus is made up of specialized cells that are
located in the brain’s ventricles. These ventricles are characterized by the production of the
cerebrospinal fluid. Furthermore, this structure provides the brain with immunological and
physical protection by having a blood brain barrier94. Immunohistochemistry was performed to
determine the levels of Tuberin in the choroid plexus at ED 14.5 and ED 16.5. Control slides
were lacking the primary antibody (Figure 8A). Sections at ED 14.5 and ED 16.5 were treated
with both primary and secondary antibody (Figure 8B). There was no significant change in
Tuberin protein levels in the choroid plexus between embryonic development time points,
p>0.05 (Figure 8C).
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Figure 8. Tuberin Protein Levels at ED 14.5 and ED 16.5 in the Choroid Plexus.
Immunohistochemistry was performed using Tuberin primary antibody. The y-axis represents
the difference in optic density of the DAB stain which ranges from 0-250 with 0 value
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representing the lighter DAB stain. The x-axis shows the brain region comparing ED 14.5 and
ED 16.5. (A) A control image of the choroid plexus lacking the primary antibody at ED 14.5 and
ED 16.5 at 10x objective showing scale bar 200µm. (B) Image of choroid plexus treated with
secondary antibody at ED 14.5 and ED 16.5. (C) Graph comparing Tuberin protein levels at ED
14.5 and ED 16.5 in the choroid plexus. Error bars represent SEM over 9 (N=9) individual
experiments. Statistical analysis was performed using single factor ANOVA. p> 0.05.

The purkinje cell layer forms the middle layer of the cerebellum which is crucial for motor
control and coordination. Purkinje cells house vital neurons that are important in the cerebellar
cortex and contain some of the largest neurons in the brain95. Brain tissue was sectioned and
controls (secondary antibody only) were obtained for both ED 14.5 and ED 16.5 (Figure 9A).
Images for sections treated with both primary and secondary antibodies were obtained at 10x
objective for both time points (Figure 9B). Tuberin protein levels were found to significantly
increase in the purkinje cell layer at the later time point during embryonic development, p< 0.05
(Figure 9C).
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Figure 9. Tuberin Protein Levels at ED 14.5 and ED 16.5 in the Purkinje Cell Layer.
Immunohistochemistry staining was performed using Tuberin primary antibody. (A) A control
image of the choroid plexus lacking the primary antibody at ED 14.5 and ED 16.5 at 10x
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magnification showing scale bar 200µm. (B) Image of purkinje cell layer treated with secondary
antibody at ED 14.5 and ED 16.5. (C) Graph comparing Tuberin protein levels at ED 14.5 and
ED 16.5 in the purkinje cell layer. Tuberin levels decreased at ED 16.5 as compared to ED 14.5.
The y-axis represents the difference in optic density of the DAB stain which ranges from 0-250
with 0 value representing the lighter DAB stain. The x-axis shows the brain region comparing
ED 14.5 and ED 16.5. Error bars represent the SEM for 9 (N=9) individual experiments.
Statistical analysis was performed using single factor ANOVA. *p< 0.05.
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II.

Tuberin mRNA Levels are Regulated during Differentiation and Cell Fate
Decisions
To determine endogenous Tuberin mRNA levels in the mouse cerebellum and in stem-

like or progenitor cell populations, primary mouse cerebellar cells were extracted and
differentiated in vitro, and collected for qrt- PCR analysis. The samples were run in a qrt-PCR
reaction. Nestin, a stemness marker, was used as a control to verify that the subpopulation of
cells is representative of the stem and/or progenitor population56. First, an early differentiation
time course, 0-24 hours, was investigated. In this time course, no significant pattern was seen for
samples run with Nestin (Figure 10A) or Tuberin (Figure 10B). The constant levels of Nestin
indicate that the cells were not differentiating during this time course. The cells were observed
under the microscope and no cellular dendrite extensions were formed at the end of the 24 hours
differentiation time point; therefore, a longer differentiation time course was carried out.
After a 72 hours differentiation time course, it was verified that the cells had been
differentiated which was indicated by the decrease in Nestin expression from 0-72 hours (Figure
11A). Interestingly, Tuberin mRNA levels also seemed to follow an overall pattern of decreasing
as the cells were differentiating (Figure 11B). This result, although not statistically significant,
may suggest the possibility of Tuberin’s role in regulating stem cell fate decisions in the normal
brain especially at early time points of development.
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A

Differentiation Time Points

B

Differentiation Time Points

Figure 10. Tuberin mRNA Levels Follow a Decreasing Pattern at Early Stages of
Differentiation
mRNA analysis of primary cerebellum cells, post-natal day 4, that were differentiated over 24
hours. (A) Nestin mRNA levels were measured using qrt-PCR analysis where data is normalized
to GAPDH and data is reported as relative quantification values (RQ). The y-axis represents
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Nestin expression levels. (B) Tuberin mRNA levels reported as RQ over 24 hours time course
for three independent experiments. The y-axis represents Tuberin expression levels. Error bars
indicate SEM of three independent qrt- PCR experiments ran in triplicate. mRNA levels are
normalized against 0 time point. p> 0.05. Statistical analysis was done one-way ANOVA.

Figure 11. Tuberin mRNA Levels are Regulated throughout Differentiation
mRNA analysis of primary cerebellum cells, post-natal day 4, differentiated over 72 hours (A).
Nestin mRNA levels normalized to GAPDH and reported as relative quantification value (RQ).
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(B) Tuberin mRNA levels reported as RQ over 0-72 hours time course for three independent
experiments. Error bars indicate SEM of three independent qrt-PCR experiments ran in triplicate.
mRNA levels are normalized against 0 time point. p> 0.05. Statistical analysis was done oneway ANOVA.
III.

Tuberin Expression Increases in the Stem Cell Population in the DAOY Cell
Line
Using the Medulloblastoma cell line, DAOY, primary and secondary neurospheres were

allowed to form under stem cell conditions (Figure 12A). To look at whether Tuberin expression
correlates with the tumour stem cell marker CD133, levels of Tuberin were analyzed in the
CD133 positive population (CD133+) using flow cytometry. Neurospheres were dissociated and
cells were stained with Tuberin-Alexa 488 and CD133-Allophycocyanin (APC) antibodies,
DAOY cells grown in monolayer were used as a negative control for the stem-cell population. In
the monolayer, the population of cells positive for CD133 was close to 0% indicating that the
stem cell population at that point was very minimal. In the primary neurosphere population,
CD133 cell percentage was approximately 18% and the percentage of cells that were labeled for
both TSC2+/ CD133+ was about 7%. This percentage increased in the secondary neurosphere
population to 18% (Figure 12B). 16% of the cells in the secondary neurospheres remained
positive for CD133 alone. In addition, looking at the percentage of cells that were TSC2 -/
CD133-, one can see that this population declines as the cells are selected for the more stem-like
populations in the secondary neurosphere conditions. These findings suggest that Tuberin is
selectively present in stem cell populations, whether Tuberin plays a functional role in cell fate
decisions is an intriguing possibility.
A similar flow cytometry analysis was conducted to investigate the percentage of stemlike cells that were positive for Tuberin along with CD133 in DAOY cells that were manipulated
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in vitro. DAOY secondary neurospheres were treated with the mTOR inhibitor Rapamycin or
were infected with a PLKO-shTSC2 lentiviral vector targeted against Tuberin mRNA.
Neurospheres lacking Rapamycin treatment and TSC2 knock-down, were used as controls. It
was observed that the percentage of Tuberin+ and Tuberin+/CD133+ labeled cells, significantly
decreased when Rapamycin was added to the neurospheres, this effect was even more
pronounced in the secondary neurospheres (Figure 12C).
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Figure 12. Flow Cytometry Analysis of CD133 and Tuberin Expression in DAOY
Neurospheres
DAOY cells were allowed to form primary and secondary neurospheres. The neurospheres were
stained with Tuberin and CD133 antibodies. (A) Representative images of primary and
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secondary DAOY neurosphere growth under necessary growth supplements. Scale bars = 20
pixels (B) Flow cytometry results reported as percentage of cells stained for Tuberin+, CD133+
and Tuberin+/CD133+. (C) Percentage of secondary neurospheres staining for Tuberin+, and
Tuberin+/ CD133+ after treating with Rapamycin and shTSC2. Error bars represent SEM.
Unpaired student’s t-test. *p< 0.05.

TSC2 Knock-Down Affects Primary Neurosphere Formation
To test the functional importance of Tuberin in neurosphere formation, DAOY cells were
seeded into stem-like conditions needed for neurosphere formation and the effects of Rapamycin
treatment and Tuberin knock-down, were monitored. Rapamycin treatment did not statistically
reduce overall neurosphere numbers (Figure 13A). However, when Tuberin was knocked-down,
the number of neurospheres formed significantly decreased (Figure 13B).
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Figure 13. Tuberin Knock-down Decreases the Number of Primary Neurospheres.
DAOY cell(A) neurospheres were treated with vehicle control (w/o Rapamycin) and(B) TSC2
knock- down. Error bars represent SEM of three independent experiments. Statistical analysis
done using student’s t- test. * p< 0.05.
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TSC2 Knock-Down Affects Secondary Neurosphere Formation
To elucidate a functional role for Tuberin on Neurosphere self-renewal, primary
neurospheres treated with Rapamycin or shRNA to knock-down Tuberin and then subcultured
and seeded into secondary neurosphere formation assays where the number of neurospheres was
counted over time. Secondary neurospheres that formed were counted at 4 days, 6 days, and 8
days, respectively. Rapamycin treatment had no statistically significant effect on self-renewal
across the six replicates (Figure 14A). Tuberin knock-down resulted in a significant decrease in
the number of secondary neurospheres that formed by day 8 (Figure 14B).
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Figure 14. Secondary Neurosphere formation is impaired in the absence to Tuberin.
DAOY cells were subcultured and plated for secondary sphere formation after treatment with
(A) 250 ng/mL of Rapamycin or vehicle control (w/o Rapamycin) or (B) scrambled shControl or
shTSC2. Total number of neurospheres are recorded on Y axis over the indicated timepoints.
Error bars indicate SEM over six independent experiments. Student’s t- test was conducted. * p<
0.05.
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DISCUSSION
Cell growth and proliferation are essential for normal development but must be tightly
regulated to prevent tumours from forming 97. This represents a particular challenge during early
development when cell growth and proliferation are occurring very rapidly. Childhood cancers,
such as those that affect the brain and the blood occur due to an inability to restrict the growth of
select cell populations. Today, we know a great deal about specific DNA mutations and deletions
that are associated with a plethora of overgrowth disorders; however, proposing suitable
treatments for these disorders requires a complete understanding of how these changes impact
growth and development. This thesis focuses on resolving some of the biology around the
protein Tuberin that is mutated in a number of human tumours, including those found in select
childhood brain tumours.
Mutations in the gene encoding Tuberin, TSC2, are the most prominent alteration in
benign tumours, known as hamartomas, which can form in many organs in the body including
the brain98. TSC2 mutations are also found in select brain cancers such as giant cell
astrocytoma99. In combination with other mutations such as those in the Sonic HedgeHog (Shh)
pathway, Tuberin mutations enhance the prevalence of the childhood brain cancer
Medulloblastoma (MB)88. Understanding how Tuberin regulates the growth of neural cell
populations may point to therapeutic directions that can benefit patients with these diseases.
Mechanistically, Tuberin is most noted for its roles as a heterodimer with the protein Hamartin,
referred to as the Tuberous Sclerosis Complex (TSC) 8.
The most well established role of the TSC is as a negative regulator of the Mammalian
Target of Rapamycin (mTOR)100. mTOR is highly conserved and it is involved in a plethora of
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cellular processes but is most noted for controlling protein synthesis 101. Hence the most obvious
role of a Tuberin mutation would be to encourage cell overgrowth via a lack of control over
protein synthesis and depleting the tumour suppressor roles of Tuberin on the cell cycle. These
functions are likely the major drivers of several of the benign hamartomas that form in TSC2
mutated patients. However, astrocytoma and MB are aggressive malignant brain cancers driven
at least in part by an aggressive population of cells that harbor stem-like properties. These cells
are termed cancer stem cells, which are capable of giving rise to different cell types within the
tumour64. While cancer stem cell populations may not arise from mutations occurring in normal
stem cells, they evolve to possess many of the qualities of a normal stem cell including the
ability to self renew. Previous studies done by Kobayashi et. al. in 1996, have shown that TSC2
knock-out mice died at ED 10 due to failure of neural tube closure, suggesting the intriguing
possibility that Tuberin may have an active and essential role in the early stages of brain
development102. One of the key objectives of this work was to determine where and when
endogenous Tuberin was found in the developing brain. Should Tuberin play an essential role in
neuro- or gliogenesis, we hypothesized that protein levels may be elevated at earlier stages of
embryonic development. We focused primarily on the structures that give rise to the cerebellum
given that this is the region of the brain where MB is derived.
To study normal protein expression in a tissue specific manner in a Balb/C mouse model,
IHC staining in cerebellum forming regions, such as the choroid plexus and purkinje cell layer
was performed. No significant differences in Tuberin protein levels were observed when
comparing various regions of the brain (olfactory bulb, cerebral cortex, choroid plexus, and
purkinje cell layer) within a given developmental time point. However, when protein levels
within the regions were compared between time points, it was observed that Tuberin protein
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levels significantly increased in the purkinje cell layer at ED 16.5. This suggests that between
these two critical time points of development and cell fate determination, Tuberin expression is
being regulated. How this is related to neurogenesis within this region requires further dissection
of the numbers of relative cell populations at ED 14.5 and 16.5 in this particular brain region,
and a close up study of the specific stem/progenitor staining for Tuberin. It is possible that the
most stem like and/or progenitor population might be increasing or proliferating at this time to
give rise to the different distinct layers of the cerebellum. It is documented in a study by Murthy
et. al. in 2001., that Tuberin expression is relatively high in the brain during brain development
especially starting at ED13103. Conversely, Tuberin levels were decreasing in other organs in the
body including the kidneys, liver, and heart103. In these organs, it is possible that the cells were
terminally differentiated; therefore, these cells do not need a high level of Tuberin to keep
cellular proliferation and growth under control. This may shed light on the significance of
Tuberin in regulating growth in mammalian brain development at early embryonic time points
especially during neurogenesis.
The increased protein levels of Tuberin observed in the purkinje cell layer may be an
indication of its regulatory role in cellular growth especially in the neural stem cells. This tumour
suppressor protein may be allowing for cellular proliferation and preventing neural cell
differentiation at this time. Tuberin might be needed to instantly increase at a certain stage in
development to regulate the proliferation and differentiation process. Analyzing normal Tuberin
levels within the purkinje cell layer is important because neurological disorders, such as Autism
Spectrum Disorders (ASDs), tend to arise in the purkinje cells of the cerebellum due to TSC2
mutations95. In a recent study, it was found that loss of TSC2 in the purkinje cells is linked to
neurological disorders95. This provides evidence for the importance of Tuberin in this region.
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The purkinje cell layer arises from the granular precursor neurons in the cerebellum.
Those neurons migrate from the granule cell layer, give rise to the purkinje cell layer, and
eventually give rise to the molecular layer104. We speculate that these granule cells possess stem
cell properties and, as they differentiate, they give rise to purkinje cells. Once the purkinje cell
layer is formed, Tuberin levels decrease, supporting the hypothesis that Tuberin is required early
in development and that Tuberin has a role in regulating both cell growth and differentiation.
Further research would be required to specifically mark the purkinje cells and look at normal
Tuberin levels at the cell level rather than the tissue as a whole.
In preliminary experiments (Appendix A Figure 1), the purkinje cell layer and choroid
plexus were stained with stem cell protein markers, such as Pax6. Pax6 is expressed in stem cells
that have not yet differentiated
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. Those brain sections were co-stained with Tuberin to assess

Tuberin co-localization with Pax6 in the stem cell population. Our early data suggests that
Tuberin is expressed in the same region as Pax6 expression in the purkinje cell layer. This
preliminary result might indicate that in fact Tuberin is expressed in stem cells where it could be
playing a role in maintaining that population and regulating differentiation, proliferation, and
overall cell fate. Further investigation would require high magnification analysis of each cell to
fully observe Tuberin and Pax6 expression together.
Future experiments, utilizing lineage tracing would be extremely useful in assessing
Tuberin localization within the neural stem cell population during cerebellum developmental
stages. One can label the cell of interest, the granule cell, with a fluorescent protein, which would
be Tuberin, and track its differentiation status in the tissue. Tissue harvesting and sectioning at
ED 14.5 and ED 16.5 could be undergone and staining with an antibody against Tuberin would
reveal Tuberin expression; identifying if Tuberin is present within these neural stem cells. In
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addition, it will be easily observed whether Tuberin is important to maintain homeostasis of the
neural stem cell population.
Interestingly, regulation by Tuberin in the regions that give rise to the cerebellum may
imply its importance in MB, given that MB tumours arise in the cerebellum 88. MB arises from a
subpopulation with cancer stem cell properties
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. Hence we optimized the isolation of primary

mouse cerebellum cells to study the importance of Tuberin during cell fate and differentiation
decisions. In a short time course of differentiation (24 hours), no significant change in Tuberin
expression was identified however, over a 4 day differentiation time course the mRNA levels of
Tuberin significantly decreased over time. This supports the hypothesis that Tuberin is needed
early on before differentiation in the stem cell or progenitor population to regulate cellular
growth and differentiation. Tuberin expression decrease would facilitate an increase in protein
synthesis, allowing for the production of specialty proteins needed for fully functional
differentiation. To further validate this hypothesis, experiments involving Tuberin overexpression in cerebellum cells would be required.

It has been previously established that

Tuberin interacts with a variety of pathways that guide and regulate cell fate and differentiation.
In a study of neuroepithelial progenitor cells from TSC2 homozygous null mice, cells cultured
from ED 10.5 had abnormal cell differentiation106. In a separate study, Tuberin knock-down
prohibited proper axon formation in actively developing neurons. In the cerebellum, an increase
in proliferation of the neural precursor cells and a decrease in neuron outgrowth were reported34.
To further support the regulatory role of Tuberin in these key cellular events, it has been noted
by a group of researchers that diseases caused by Tuberin mutations are linked to abnormal
differentiation, further supporting the involvement of Tuberin in the regulation of cell fate and
differentiation 34.
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To investigate the effects of Tuberin on stemness properties, primary extracted cerebellum
cells were exposed to lentiviral Tuberin knock-down. Preliminary results from a neurosphere
formation assay, showed that neurosphere size increased (Appendix A Figure 2). This result
supports that the loss of the tumour suppressor protein causes uncontrollable division, whether
the increased size is due to proliferation of select populations or truly through an increase in selfrenewal needs to be further explored using secondary neurosphere forming assays and cell pair
assays.
CD133 has been shown to be expressed in cancer stem cells. Using CD133 as the stem
cell marker for the Shh derived Medulloblastoma cell-line, DAOY, cells were cultured under
stem cell conditions promoting the formation of neurospheres96. Through the use of flow
cytometry, the collected neurospheres were sorted from a single cell suspension and stained with
specific antibodies. In the monolayer, the CD133+ population was almost non-existent, which is
expected since the cells at this stage are less stem-like. The CD133+ cell population is expected
to increase as the cells become more stem-like going from monolayer to primary and then
secondary neurospheres. In comparison, the percentage of cells that were Tuberin+/CD133+
increased as cells were passaged as neurospheres. This result indicates that Tuberin is present in
the stem cell population, consistent with endogenous levels being elevated in select populations
at earlier stages of development. Whether Tuberin plays a direct role on the functional stem cell
properties cannot be determined from this assay alone.
To elucidate the role of Tuberin in the stem cell population, DAOY cells were
manipulated by lentiviral infection to knock-down Tuberin. Cells infected with a lentiviral
shRNA scrambled vector served as the control for the experiment. The percentage of cells that
were Tuberin+/CD133+ significantly decreased when compared to the control, as expected. There
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were fewer neurospheres formed when Tuberin was knocked-down, providing good support that
Tuberin is essential for the stem cell population self-renewal. Moreover, a group of cells were
treated with Rapamycin, which halts mTOR activity and blocks protein synthesis/cell growth.
Through experimental treatment of the cells with Rapamycin, it was observed that there is a
decrease in the Tuberin+/ CD133+ population and a decrease in neurosphere numbers, confirming
that mTOR regulation is necessary for the stem cell population of self renewal. Our neurosphere
experiments confirm that Tuberin plays a critical role in the maintenance of the stem cell
population; whether it is through self-renewal, survival or proliferation remains to be further
determined. Rapamycin alone did not have a significant effect on neurosphere number which
suggests that Tuberin role in stem-cell self-renewal is either not only mediated through mTOR,
or that the appropriate stimulus was not provided for testing (ie. a differentiation stimuli). An
experiment that could shed light on the mechanism of Tuberin function would be to treat cells
that are Tuberin null with Rapamycin to determine whether the cells would be able to self-renew
and proliferate or if Rapamycin would completely inhibit their growth with the lack of Tuberin
in the cells.
We assess self-renewal through secondary neurosphere formation in Tuberin null cells and
Rapamycin treated cells. Over an 8 day period, there was a significant decrease in Tuberin in the
secondary neurospheres. A decline in the number of neurospheres was also seen with Rapamycin
treatment although findings were not statistically significant. This experiment, supports that
Tuberin may be essential in regulating the stem cell population. When Tuberin is knocked-down,
the cells start to die or growth is halted due to misregulation of the the mTOR regulatory
pathway. To further enhance this result, investigating the activity of mTOR downstream
effectors, such as S6K, would provide insight regarding the possible misregulation of mTOR.
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Overall, this research emphasizes a potential role for Tuberin in regulating and
maintaining the progenitor stem cell population. We have determined that Tuberin is present, and
even elevated, in specific regions of the brain at early time points of development when
neurogenesis is at its peak. Tuberin seems to be regulating the process of cell fate decisions in
instances where it halts cell proliferation and allows for terminal cell differentiation. Assessing
Tuberin levels in primary extracted cerebellum cells is one of the few studies that try to link
Tuberin regulation with stem cell fate decisions. Being able to correlate Tuberin expression with
tumour stem cells, such as those in MB cells, will help imply how these cancer stem cells are
driving tumourogenesis. One of the limitations to working with primary extracted cerebellum
cells is that they are short lived and extraction is both challenging and time consuming. New
advances in technology such as the CRISPR/CAS9 tool, allows researchers to manipulate the
genome. Therefore, CRISPR/CAS9 technology would enable us to determine the role of select
TSC2 mutations in any cell type selected in the absence of endogenous wild-type protein. This
would enable us to find answers faster and more efficiently. The CRISPR/CAS9 system would
also allow us to knock-in select TSC2 mutations in vivo. With the advent of this new exciting
technology we can take the results obtained herein to a new level to determine whether Tuberin
signaling has potential as a therapeutic target for select forms of tumour disorders.
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Appendix A

A

B

C

Figure 1. Tuberin and Pax6 are Expressed Around the Purkinje Cell Layer Area.
Purkinje cell layer area at ED 16.5 was stained using Immunofluorescence. (A) Control section
lacking the primary antibody and expressing DAPI nuclear stain. (B) Tuberin expression shown
in red around the PCL. (C) Pax6 expression shown in red around the PCL. All images were
taken with a 10x objective
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Figure 2. Tuberin Knock-down in Primary Cerebellm Cells shows and Increase in
Neurosphere Size
Stem-like cells from the mouse cerebellum at PN=4 were stimulated to form neurospheres. (A)
Image of neurospheres after shTSC2 control infection. (B) Cells treated with shTSC2 infection
and (C) Cells treated with a different knock-down construct of shTSC2. Images were taken in
bright field, GFP, and an overlay of both fields, respectively. Green fluorescence indicates
successful knock-down.

61

REFERENCES
1.

Oren, M. Tumour suppressors: Teaming up to restrain cancer. Nature 391, 233–234 (1998).

2.

Hutchinson, E. Alfred Knudson and his two-hit hypothesis. Lancet Oncol. 2, 642–645 (2001).

3.

Knudson, a G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U.
S. A. 68, 820–823 (1971).

4.

Green, A. J., Smith, M. & Yates, J. R. Loss of heterozygosity on chromosome 16p13.3 in
hamartomas from tuberous sclerosis patients. Nat. Genet. 6, 193–196 (1994).

5.

Young, J. & Povey, S. The genetic basis of tuberous sclerosis. Mol. Med. Today 4, 313–9 (1998).

6.

Sarbassov, D. D., Ali, S. M. & Sabatini, D. M. Growing roles for the mTOR pathway. Curr. Opin.
Cell Biol. 17, 596–603 (2005).

7.

Burgstaller, S. et al. Tuberin, p27 and mTOR in different cells. Amino Acids 36, 297–302 (2009).

8.

Rosner, M., Hanneder, M., Siegel, N., Valli, A. & Hengstschläger, M. The tuberous sclerosis gene
products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting
partners. Mutat. Res. 658, 234–46 (2008).

9.

Jones, A. C. et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic
correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet. 64, 1305–15 (1999).

10.

van Slegtenhorst, M. et al. Identification of the tuberous sclerosis gene TSC1 on chromosome
9q34. Science 277, 805–808 (1997).

11.

Nellist, M. et al. Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic
chaperone for hamartin. J. Biol. Chem. 274, 35647–35652 (1999).

12.

Abu Khatir, B. Tuberin Expression and Function in Mammalian Development. (University of
Windsor, 2013).

13.

Benvenuto, G. et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell
growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination.
Oncogene 19, 6306–6316 (2000).

14.

Potter, C. J., Pedraza, L. G. & Xu, T. Akt regulates growth by directly phosphorylating Tsc2. Nat.
Cell Biol. 4, 658–65 (2002).

15.

Inoki, K. et al. TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by
AMPK and GSK3 to Regulate Cell Growth. Cell 126, 955–968 (2006).

16.

Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S. H. RAFT1: A
mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to
yeast TORs. Cell 78, 35–43 (1994).

17.

Jacinto, E. What controls TOR? IUBMB Life 60, 483–96 (2008).

18.

Fidalgo da Silva, E. et al. The tumor suppressor tuberin regulates mitotic onset through the cellular
localization of cyclin B1. Cell Cycle 10, 3129–3139 (2011).

62

19.

Alberts, B. et al. Molecular Biology of the Cell, Fourth Edition. Molecular Biology (2002).

20.

College, K. Genetics and Development. (2015). at
<http://biology.kenyon.edu/courses/biol114/index.html>

21.

Cecie Starr, Ralph Taggart, Christine Evers, L. S. Animal Structure and Function. (Nelson
Education, 2012).

22.

Sadler, T. W. Embryology of neural tube development. Am. J. Med. Genet. 135C, 2–8 (2005).

23.

Gilbert, S. F. Developmental Biology. (Sinauer Associates, 2000).

24.

Götz, M. & Huttner, W. B. The cell biology of neurogenesis. Nat Rev Mol Cell Biol 6, 777–788
(2005).

25.

Stiles, J. & Jernigan, T. L. The basics of brain development. Neuropsychol. Rev. 20, 327–348
(2010).

26.

Wilson, S. I. & Edlund, T. Neural induction: toward a unifying mechanism. Nat Neurosci 4 Suppl,
1161–1168 (2001).

27.

Wilson, L. & Maden, M. The mechanisms of dorsoventral patterning in the vertebrate neural tube.
Dev. Biol. 282, 1–13 (2005).

28.

Iacopetti, P. et al. Expression of the antiproliferative gene TIS21 at the onset of neurogenesis
identifies single neuroepithelial cells that switch from proliferative to neuron-generating division.
Proc. Natl. Acad. Sci. U. S. A. 96, 4639–4644 (1999).

29.

Northrup, H. & Volcik, K. a. Spina bifida and other neural tube defects. Curr. Probl. Pediatr. 30,
313–332 (2000).

30.

Crane, J. F. & Trainor, P. a. Neural crest stem and progenitor cells. Annu. Rev. Cell Dev. Biol. 22,
267–286 (2006).

31.

Ulloa, F. & Martí, E. Wnt won the war: Antagonistic role of Wnt over Shh controls dorso-ventral
patterning of the vertebrate neural tube. Dev. Dyn. 239, 69–76 (2010).

32.

Nguyen, V. H. et al. Dorsal and intermediate neuronal cell types of the spinal cord are established
by a BMP signaling pathway. Development 127, 1209–1220 (2000).

33.

Taverna, E., Götz, M. & Huttner, W. B. The Cell Biology of Neurogenesis: Toward an
Understanding of the Development and Evolution of the Neocortex. Annual review of cell and
developmental biology (2014). doi:10.1146/annurev-cellbio-101011-155801

34.

Floricel, F. et al. Antisense suppression of TSC1 gene product, hamartin, enhances neurite
outgrowth in NGF-treated PC12h cells. Brain Dev 29, 502–509 (2007).

35.

Choi, Y. J. et al. Tuberous sclerosis complex proteins control axon formation. Genes Dev 22,
2485–2495 (2008).

36.

Tavazoie, S. F., Alvarez, V. a, Ridenour, D. a, Kwiatkowski, D. J. & Sabatini, B. L. Regulation of
neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat. Neurosci. 8,
1727–1734 (2005).

63

37.

Butts, T., Green, M. J. & Wingate, R. J. Development of the cerebellum: simple steps to make a
‘little brain’. Development 141, 4031–4041 (2014).

38.

Buckner, R. L. The cerebellum and cognitive function: 25 years of insight from anatomy and
neuroimaging. Neuron 80, 807–15 (2013).

39.

Bloch-Gallego, E., Causeret, F., Ezan, F., Backer, S. & Hidalgo-Sánchez, M. Development of
precerebellar nuclei: instructive factors and intracellular mediators in neuronal migration, survival
and axon pathfinding. Brain Res. Brain Res. Rev. 49, 253–66 (2005).

40.

Tsai, L. H. & Gleeson, J. G. Nucleokinesis in neuronal migration. Neuron 46, 383–388 (2005).

41.

Purves D, Augustine GJ, F. D. Neuroscience. (Sinauer Associates, 2001).

42.

Silbereis, J. et al. Astroglial cells in the external granular layer are precursors of cerebellar granule
neurons in neonates. Mol. Cell. Neurosci. 44, 362–73 (2010).

43.

Smeyne, R. J. & Goldowitz, D. Development and death of external granular layer cells in the
weaver mouse cerebellum: a quantitative study. J. Neurosci. 9, 1608–20 (1989).

44.

T. Tabata, M. K. Synaptic Plasticity in the Cerebellum. Springer 63–86

45.

Health, N. I. of. Stem Cell Basics. 1–26 (2015).

46.

Slack, J. M. W. Origin of stem cells in organogenesis. Science 322, 1498–1501 (2008).

47.

Sell, S. On the Stem Cell Origin of Cancer. Am. J. Pathol. 176, 2584–2594 (2010).

48.

Morrison, S. J. & Kimble, J. Asymmetric and symmetric stem-cell divisions in development and
cancer. Nature 441, 1068–1074 (2006).

49.

Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem
cells. Nature 414, 105–11 (2001).

50.

Shahriyari, L. & Komarova, N. L. Symmetric vs. Asymmetric Stem Cell Divisions: An Adaptation
against Cancer? PLoS One 8, e76195 (2013).

51.

Shahriyari, L. & Komarova, N. L. Symmetric vs. asymmetric stem cell divisions: an adaptation
against cancer? PLoS One 8, e76195 (2013).

52.

Furusawa, C. & Kaneko, K. A Dynamical-Systems View of Stem Cell Biology. Science (80-. ).
338, 215–217 (2012).

53.

Nottebohm, F. From bird song to neurogenesis. Sci. Am. 260, 74–79 (1989).

54.

Kornblum, H. I. Introduction to neural stem cells. Stroke. 38, 810–6 (2007).

55.

Reynolds, B. A. & Weiss, S. Generation of neurons and astrocytes from isolated cells of the adult
mammalian central nervous system. Science (80-. ). 255, 1707–1710 (1992).

56.

Wiese, C. et al. Nestin expression - A property of multi-lineage progenitor cells? Cell. Mol. Life
Sci. 61, 2510–2522 (2004).

57.

Raff, M. C., Miller, R. H. & Noble, M. A glial progenitor cell that develops in vitro into an
astrocyte or an oligodendrocyte depending on culture medium. Nature 303, 390–396 (1983).
64

58.

Luskin, M. B. Restricted proliferation and migration of postnatally generated neurons derived
from the forebrain subventricular zone. Neuron 11, 173–189 (1993).

59.

Bolós, V., Grego-Bessa, J. & De La Pompa, J. L. Notch signaling in development and cancer.
Endocr. Rev. 28, 339–363 (2007).

60.

Hori, K., Sen, A. & Artavanis-Tsakonas, S. Notch signaling at a glance. J. Cell Sci. 126, 2135–40
(2013).

61.

Ma, J. et al. Mammalian target of rapamycin regulates murine and human cell differentiation
through STAT3/p63/Jagged/Notch cascade. J. Clin. Invest. 120, 103–114 (2010).

62.

Huang, S. & Houghton, P. J. Targeting mTOR signaling for cancer therapy. Curr. Opin.
Pharmacol. 3, 371–377 (2003).

63.

Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401
(2004).

64.

Singh, S. K. et al. Identification of a Cancer Stem Cell in Human Brain Tumors. CANCER Res.
63, 5821–5828 (2003).

65.

Shackleton, M., Quintana, E., Fearon, E. R. & Morrison, S. J. Heterogeneity in Cancer: Cancer
Stem Cells versus Clonal Evolution. Cell 138, 822–829 (2009).

66.

Tan, B. T., Park, C. Y., Ailles, L. E. & Weissman, I. L. The cancer stem cell hypothesis: a work in
progress. Lab. Invest. 86, 1203–1207 (2006).

67.

Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID
mice. Nature 367, 645–648 (1994).

68.

Miller, C. R. & Perry, A. Glioblastoma. Arch. Pathol. Lab. Med. 131, 397–406 (2007).

69.

Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from
human glioblastoma. Cancer Res. 64, 7011–7021 (2004).

70.

Minniti, G., Muni, R., Lanzetta, G., Marchetti, P. & Maurizi Enrici, R. Chemotherapy for
glioblastoma: Current treatment and future perspectives for cytotoxic and targeted agents.
Anticancer Res. 29, 5171–5184 (2009).

71.

Facchino, S., Abdouh, M. & Bernier, G. Brain cancer stem cells: Current status on glioblastoma
multiforme. Cancers (Basel). 3, 1777–1797 (2011).

72.

Goffart, N., Kroonen, J. & Rogister, B. Glioblastoma-initiating cells: Relationship with neural
stem cells and the micro-environment. Cancers (Basel). 5, 1049–1071 (2013).

73.

Canada, B. T. F. of. Medulloblastoma: Overview. (2015). at <http://neuropathologyweb.org/chapter7/chapter7cMedulloblastoma.html>

74.

Association, A. B. T. Medulloblastoma. www.abta.org 4–8 (2012).

75.

DeSouza, R.-M., Jones, B. R. T., Lowis, S. P. & Kurian, K. M. Pediatric medulloblastoma - update
on molecular classification driving targeted therapies. Front. Oncol. 4, 176 (2014).

76.

Cohen, N. R., Phipps, K., Harding, B. & Jacques, T. S. Is CSF cytology a useful diagnostic
65

procedure in staging paediatric CNS tumours? Cytopathology 20, 256–260 (2009).
77.

De Braganca, K. C. & Packer, R. J. Treatment options for medulloblastoma and CNS primitive
neuroectodermal tumor (PNET). Curr. Treat. Options Neurol. 15, 593–606 (2013).

78.

Agamanolis, D. P. M. D. in Neuropathology: Tumors of the Central Nervous System (ed. Herrick,
Mike Gemmer. Dr. Maie K., Richard Koneval, A. M.) Interactive Course Pages 1–4 (2012). at
<http://neuropathology-web.org/chapter7/chapter7cMedulloblastoma.html>

79.

Gilbertson, R. J. Medulloblastoma: Signalling a change in treatment. Lancet Oncol. 5, 209–218
(2004).

80.

Aguilar, D. et al. Differentiation in medulloblastomas: immunohistochemical study of twenty-one
cases. Appl.Pathol. 7, 277–284 (1989).

81.

Northcott, P. a. et al. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol.
29, 1408–1414 (2011).

82.

Gibson, P. et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 468,
1095–1099 (2010).

83.

Cheang, M. C. U., van de Rijn, M. & Nielsen, T. O. The Origins of Medulloblastoma Subtypes.
Annu. Rev. Pathol. Dis. 3, 67–97 (2008).

84.

Nusse, R. Wnt signaling in disease and in development. Cell Res. 15, 28–32 (2005).

85.

Klaus, A. & Birchmeier, W. Wnt signalling and its impact on development and cancer. Nat. Rev.
Cancer 8, 387–398 (2008).

86.

Moon, R. T., Kohn, A. D., De Ferrari, G. V & Kaykas, A. WNT and beta-catenin signalling:
diseases and therapies. Nat. Rev. Genet. 5, 691–701 (2004).

87.

Markku Varjosalo and Jussi Taipale. Hedgehog: Functions and Mechanisms. Genes Dev. 2, 2454–
2472 (2008).

88.

Bhatia, B. et al. Tuberous sclerosis complex suppression in cerebellar development and
medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1
localization. Cancer Res. 69, 7224–34 (2009).

89.

Nüsslein-Volhard, C. & Wieschaus, E. Mutations affecting segment number and polarity in
Drosophila. Nature 287, 795–801 (1980).

90.

Singh, S. et al. Sonic hedgehog mutations identified in holoprosencephaly patients can act in a
dominant negative manner. Hum. Genet. 125, 95–103 (2009).

91.

Bhatia, B. et al. Tuberous sclerosis complex suppression in cerebellar development and
medulloblastoma: Separate regulation of mammalian target of rapamycin activity and p27Kip1
localization. Cancer Res. 69, 7224–7234 (2009).

92.

Laboratories, J. Breeding Strategies for Maintaining Colonies of Laboratory Mice. (2015).

93.

Paxinos, G. & Franklin, K. B. J. The mouse brain in stereotaxic coordinates. Academic Press 2nd,
(2004).

66

94.

Redzic B, Preston E, Duncan A, Chodobski A, S.-C. J. The choroid plexus-cerebrospinal fluid
system: from development to aging. Dep. Pharmacol. (2005).

95.

Reith, R. M., Way, S., McKenna 3rd, J., Haines, K. & Gambello, M. J. Loss of the tuberous
sclerosis complex protein tuberin causes Purkinje cell degeneration. Neurobiol Dis 43, 113–122
(2011).

96.

Wu, Y. & Wu, P. Y. CD133 as a marker for cancer stem cells: progresses and concerns. Stem
Cells Dev. 18, 1127–1134 (2009).

97.

Bai, X. & Jiang, Y. Key factors in mTOR regulation. Cell. Mol. Life Sci. 67, 239–253 (2010).

98.

Zeng, L. H. et al. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1
inactivation in a mouse model of Tuberous Sclerosis Complex. Hum. Mol. Genet. 20, 445–454
(2011).

99.

Gutmann, D. H. et al. Expression of the tuberous sclerosis complex gene products, hamartin and
tuberin, in central nervous system tissues. Acta Neuropathol. 99, 223–30 (2000).

100.

Schmelzle, T. & Hall, M. N. TOR, a central controller of cell growth. Cell 103, 253–262 (2000).

101.

Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124,
471–484 (2006).

102.

Orimoto, K., Tsuchiya, H., Kobayashi, T., Matsuda, T. & Hino, O. Suppression of the neoplastic
phenotype by replacement of the Tsc2 gene in Eker rat renal carcinoma cells. Biochem Biophys
Res Commun 219, 70–75 (1996).

103.

Murthy, V. et al. Developmental expression of the tuberous sclerosis proteins tuberin and
hamartin. Acta Neuropathol 101, 202–210 (2001).

104.

Hibi, M. & Shimizu, T. Development of the cerebellum and cerebellar neural circuits. Dev.
Neurobiol. 72, 282–301 (2012).

105.

Zhang, X. et al. Pax6 is a human neuroectoderm cell fate determinant. Cell Stem Cell 7, 90–100
(2010).

106.

Onda, H. et al. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and
show activation of an mTOR pathway. Mol. Cell. Neurosci. 21, 561–574 (2002).

67

VITA AUCTORIS

NAME:

Bashaer Abu Khatir

PLACE OF BIRTH:

United Arab Emirates, Al-Ain

YEAR OF BIRTH:

1991

EDUCATION:

Sandwich Secondary School, Windsor, ON, 2009
University of Windsor, B.Sc., Windsor, ON, 2013
University of Windsor, M.Sc., Windsor, ON, 2016

68

